Marie-Claire Aldenhoff
University of Liège
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marie-Claire Aldenhoff.
Clinical Chemistry and Laboratory Medicine | 2002
Jean-Paul Chapelle; Bernard Dubois; Christophe Bovy; Marie-Claire Aldenhoff; Jacques Gielen; Georges Rorive
Abstract Cardiac troponins (cTnT and cTnI) are useful tools for risk stratification in patients with unstable angina. However, their value in patients with renal failure has been questioned. In this study, we determined cTnT and cTnI at 3-month intervals during 9 months in 97 chronic renal failure (CRF) patients treated with hemodialysis. cTnT was measured using a third generation immunoassay and cTnI by fluorimetric immunoassay with a detection limit similar to that of cTnT (0.01 μg/l). In the renal patients without coronary heart disease (CHD(−) group), cTnT was more frequently elevated above cut-off for acute myocardial infarction (AMI) (up to 21.6%) than cTnI (no patient). In the absence of CHD, cTnT levels were positively correlated to age, and more than half of the CHD(−) patients aged over 60 years had cTnT levels above the upper reference limit (URL) of 0.04 μg/l (0.059±0.042 μg/l). cTnI increased with age in parallel to cTnT but mean levels did not exceed the URL of 0.08 μg/l in the CHD(−) patients aged over 60 years (0.036±0.031 μg/l). In the patients with documented cardiac events (CHD(+)) we found higher troponin levels than in the CHD(−) patients of the corresponding age, but for cTnI the differences between CHD(+) and CHD(−) patients were significant in the patients aged ≤60 years only (0.049±0.054 vs.0.019±0.018 μg/l, p<0.05). For cTnT, the differences between patients with and without coronary events also tended to be less important in the eldest patients. There was a significant correlation between cTnI and cTnT levels in the CHD(−) and in the CHD(+) groups. Changes in the plasma levels of cardiac troponins are common in hemodialysis patients in the absence of CHD, and advanced age appears to amplify these changes. The reason could be that most hemodialysis patients with advanced age have subclinical lesions and demonstrate release characteristics of troponins that compare to those in patients with symptomatic coronary events. Therefore, it will be important to analyze troponin elevations above the URL or above the cut-off concentration for AMI in asymptomatic renal patients in relation to prognosis.
Clinical Chemistry | 2000
Jean-Paul Chapelle; Marie-Claire Aldenhoff; Luc Pierard; Jacques Gielen
Archive | 2009
Jelda Teixeira; Caroline Le Goff; Marie-Claire Aldenhoff; Christophe Bovy; Bernard Dubois; Jean-Marie Krzesinski; Jean-Paul Chapelle
Archive | 2008
Jelda Teixeira; Marie-Claire Aldenhoff; Christophe Bovy; Bernard Dubois; Jean-Marie Krzesinski; Jean-Paul Chapelle
Archive | 2007
Caroline Le Goff; Marie-Claire Aldenhoff; Christophe Bovy; Jean-Marie Krzesinski; Jean-Paul Chapelle
Immuno-analyse & Biologie Specialisee | 2007
C. Le Goff; Christophe Bovy; Marie-Claire Aldenhoff; Jean-Marie Krzesinski; Jean-Paul Chapelle
Acta Clinica Belgica | 2007
Jelda Teixeira; Marie-Claire Aldenhoff; Jean-Paul Chapelle
Archive | 2006
Caroline Le Goff; Marie-Claire Aldenhoff; Christophe Bovy; Jean-Marie Krzesinski; Jean-Paul Chapelle
Clinical Chemistry and Laboratory Medicine | 2003
Jean-Paul Chapelle; Marie-Claire Aldenhoff; Jacques Gielen
Clinical Chemistry and Laboratory Medicine | 2003
Jean-Paul Chapelle; Marie-Claire Aldenhoff; Joël Pincemail; Jacques Gielen